Sigyn Therapeutics (SIGY) Cash & Equivalents (2016 - 2025)

Sigyn Therapeutics has reported Cash & Equivalents for 10 years, with the latest figure at $85571.0 in Q3 2025.

• Quarterly Cash & Equivalents fell 48.07% year-over-year to $85571.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $85571.0 (down 48.07% YoY) and the FY2024 annual result came in at $12144.0, up 3.88% from the prior year.
• Cash & Equivalents improved to $85571.0 in Q3 2025 per SIGY's latest filing, from $459.0 in the prior quarter.
• Over five years, Cash & Equivalents peaked at $1.1 million in Q2 2021 and troughed at $459.0 in Q2 2025.
• A 5-year average of $148461.3 and a median of $32838.0 in 2024 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2021 and 2022: Cash & Equivalents jumped 116383.19% in 2021, then plunged 99.31% in 2022.
• Over 5 years, Cash & Equivalents stood at $340956.0 in 2021, then plunged by 97.55% to $8356.0 in 2022, then surged by 39.9% to $11690.0 in 2023, then advanced by 3.88% to $12144.0 in 2024, then soared by 604.64% to $85571.0 in 2025.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $85571.0, $459.0, and $12895.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.